Regeneration of vital tooth pulp

Patent metadata

Field	Value
Publication number	US-12285545-B2
Application number	US-201916979038-A
Country	US
Kind code	B2
Filing date	Mar 20, 2019
Priority date	Mar 20, 2018
Publication date	Apr 29, 2025
Grant date	Apr 29, 2025

Abstract

Methods of regenerating vital tooth tissue in situ after endodontic therapy include introducing a hydrogel scaffold into a root canal of a tooth in a patient after native pulp has been removed from the root canal. The hydrogel scaffold may comprise a sponge scaffold, and can be acellular. The hydrogel scaffold can contain chemotactic, angiogenic, neurogenic, and/or immunomodulatory biofactors that cause infiltration of endogenous cells from the patient into the root canal. Alternatively, such biofactors/drugs can be administered to the patient separately from the hydrogel scaffold. The hydrogel scaffold can fill the periapical space of an abscessed root.

First claim

The invention claimed is:

1. A method of regenerating vital tooth tissue in situ after endodontic therapy, comprising:
forming an opening in a tooth in a patient and removing native pulp from a root canal of the tooth;
after removing the native pulp from the root canal, introducing a hydrogel scaffold into the root canal, and
sealing the opening after introducing the hydrogel scaffold into the root canal; and wherein:
the hydrogel scaffold comprises an acellular heparin and gelatin hydrogel scaffold;
the gelatin:heparin mass ratio is about 3 to 2;
the hydrogel scaffold has sufficiently low viscosity such that it flows into smaller accessory canals of the root canal and fills substantially an entire space within the root canal, and thereby provides obturation to block blood from entering the root canal;
the hydrogel scaffold comprises a collagen-derived amino acid polymer that contains cell-binding motifs and is biodegradable via enzymatic degradation, and a sulfated polysaccharide that is anionic and is biodegradable via enzymatic degradation; and
the collagen-derived amino acid polymer comprises gelatin and the sulfated polysaccharide comprises heparin.

2. The method of claim 1 , wherein the hydrogel scaffold comprises chemotactic, angiogenic, neurogenic, and immunomodulatory biofactors that cause infiltration of endogenous cells from the patient into the root canal.

3. The method of claim 1 , wherein the hydrogel scaffold is free of drugs and biofactors other than the hydrogel scaffold itself, and the method comprises:
administering, separate from the hydrogel scaffold, chemotactic, angiogenic, neurogenic, and immunomodulatory biofactors that inhibit inflammation or promote infiltration of endogenous cells from the patient into the root canal.

4. The method of claim 1 , wherein the hydrogel scaffold is carried within a sponge scaffold and the sponge scaffold is introduced into the root canal with the hydrogel scaffold.

5. The method of claim 1 , further comprising treating the patient with an anti-inflammatory drug regimen.

6. The method of claim 5 , wherein treating the patient with the anti-inflammatory regimen comprises treatment with corticosteroids or non-steroidal anti-inflammatory drugs.

7. The method of claim 1 , further comprising performing a tooth restoration procedure on the tooth after the hydrogel scaffold is introduced and the opening is sealed.

8. The method of claim 1 , further comprising opening an apex of the tooth to provide a conduit for cellular infiltration to occur.

9. The method of claim 1 , wherein the hydrogel scaffold fills periapical space of an abscessed root.

10. The method of claim 1 , wherein the hydrogel scaffold comprises in situ crosslinking methacrylated gelatin and heparin.

11. The method of claim 2 , wherein the hydrogel scaffold comprises drug binding moieties.

12. The method claim 4 , wherein the sponge scaffold comprises thermally crosslinked gelatin.

13. The method of claim 2 , wherein the biofactors comprise chemokines, cytokines, lymphokines, growth factors, neuroregulatory factors, immunomodulatory, or chemical agonists.

14. The method of claim 2 , wherein the biofactors comprise corticosteroids, purmorphamine, Filgrastim or Epoetin alfa.

15. The method of claim 2 , wherein the biofactors suppress an acute inflammatory reaction caused by endodontic therapy in the periapical space.

16. The method of claim 1 , wherein the hydrogel scaffold expands within the root canal to fill substantially the entire space within the root canal.

17. The method of claim 1 , wherein the heparin and gelatin are about 8% w/v of the hydrogel scaffold.

18. The method of claim 1 , wherein the heparin is covalently crosslinked to the hydrogel scaffold.

Assignees

• Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education

Inventors

• Taboas Juan M
• Ray Herbert L
• Chen Jingming
• Donnelly Patrick Eugene
• Swenson Tyler

Classifications

• A61L2430/12

  for dental implants or prostheses · CPC title

• A61L2400/06

  Flowable or injectable implant compositions · CPC title

• A61L2300/426

  Immunomodulating agents, i.e. cytokines, interleukins, interferons · CPC title

• A61L2300/414

  Growth factors · CPC title

• A61L2300/41

  Anti-inflammatory agents, e.g. NSAIDs · CPC title